Ironwood Pharmaceuticals, Inc. revised earnings guidance for its Fiscal Year 2024. Total Revenue reported its Prior 2024 Guidance of $435 to $455 million as compared to Revised 2024 Guidance of revenue to be $405 to $425 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +3.96% | +5.88% | -44.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.93% | 1B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024